Exelixis, Inc. (NASDAQ:EXEL) Shares Bought by Capital Management Corp VA

Capital Management Corp VA lifted its stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 7.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 365,270 shares of the biotechnology company's stock after acquiring an additional 25,350 shares during the quarter. Exelixis accounts for about 1.7% of Capital Management Corp VA's portfolio, making the stock its 26th largest position. Capital Management Corp VA owned 0.13% of Exelixis worth $9,479,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of the stock. V Square Quantitative Management LLC acquired a new position in shares of Exelixis during the third quarter worth $30,000. Park Place Capital Corp acquired a new position in Exelixis in the second quarter valued at $45,000. GAMMA Investing LLC boosted its stake in Exelixis by 107.9% in the second quarter. GAMMA Investing LLC now owns 2,006 shares of the biotechnology company's stock valued at $45,000 after acquiring an additional 1,041 shares in the last quarter. EntryPoint Capital LLC boosted its stake in Exelixis by 537.2% in the first quarter. EntryPoint Capital LLC now owns 2,071 shares of the biotechnology company's stock valued at $49,000 after acquiring an additional 1,746 shares in the last quarter. Finally, Essex Investment Management Co. LLC acquired a new position in Exelixis in the third quarter valued at $74,000. Hedge funds and other institutional investors own 85.27% of the company's stock.

Insider Activity

In other news, Director Maria C. Freire sold 8,250 shares of the stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $26.56, for a total value of $219,120.00. Following the sale, the director now directly owns 91,007 shares in the company, valued at $2,417,145.92. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, EVP Dana Aftab sold 95,000 shares of the firm's stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $25.00, for a total transaction of $2,375,000.00. Following the sale, the executive vice president now owns 520,990 shares in the company, valued at approximately $13,024,750. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Maria C. Freire sold 8,250 shares of the firm's stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $26.56, for a total transaction of $219,120.00. Following the sale, the director now owns 91,007 shares in the company, valued at approximately $2,417,145.92. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 354,020 shares of company stock worth $9,386,366 over the last ninety days. 2.85% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

EXEL has been the subject of several research analyst reports. HC Wainwright restated a "buy" rating and issued a $29.00 price objective on shares of Exelixis in a research note on Wednesday, September 18th. Piper Sandler upped their price objective on shares of Exelixis from $33.00 to $36.00 and gave the company an "overweight" rating in a research note on Wednesday, October 30th. Wells Fargo & Company increased their target price on shares of Exelixis from $32.00 to $36.00 and gave the stock an "overweight" rating in a research note on Wednesday, October 30th. JMP Securities reiterated a "market outperform" rating and set a $29.00 target price on shares of Exelixis in a research note on Friday, October 11th. Finally, Morgan Stanley increased their target price on shares of Exelixis from $26.00 to $28.00 and gave the stock an "equal weight" rating in a research note on Friday, October 11th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $31.44.

Exelixis Price Performance

Exelixis stock traded up $0.48 during mid-day trading on Tuesday, reaching $34.77. The company had a trading volume of 2,754,724 shares, compared to its average volume of 2,076,046. Exelixis, Inc. has a 1 year low of $19.20 and a 1 year high of $35.15. The company has a market capitalization of $9.93 billion, a P/E ratio of 22.08, a P/E/G ratio of 0.92 and a beta of 0.51. The stock's 50-day simple moving average is $27.30 and its 200-day simple moving average is $24.39.

Exelixis (NASDAQ:EXEL - Get Free Report) last issued its earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.36 by $0.04. Exelixis had a net margin of 22.43% and a return on equity of 20.99%. The company had revenue of $539.50 million during the quarter, compared to analysts' expectations of $490.31 million. During the same period last year, the company posted $0.10 earnings per share. The firm's quarterly revenue was up 14.3% compared to the same quarter last year. On average, equities analysts forecast that Exelixis, Inc. will post 1.59 EPS for the current fiscal year.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.